Palatin Hosts Thought Leader Webinar on Dry Eye Disease |


CRANBURY, NJ, March 3, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing innovative drugs based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that she will host a Key Opinion Leaders (KOL) Webinar on the Unmet Medical Need in the Treatment of Patients with Dry Eye Disease (DED) on Monday, March 7, 2022 at 10:30 a.m. ET.

The webinar will feature a presentation by KOL Eric D. Donnenfeld, MD, of OCLI Vision, who will discuss the current treatment landscape and unmet medical needs in the treatment of patients with DED.

Medical Director of Palatin Technologies Michael Raizman, MD will also discuss their Phase 3 trial for PL9643 in patients with dry eye disease. The MELODY-1 clinical study is a multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of the melanocortin agonist, PL9643 Ophthalmic Solution, compared to vehicle in subjects with of SSO. The study is designed to enroll up to 400 patients across multiple US sites, and initial results are currently expected in the second half of 2022.

The presentation will be followed by a question-and-answer session with Dr. Donnenfeld, Dr. Raizman and Palatin’s senior management. To register for the webinar and participate in the webcast, please visit the Palatin website at or click here.

Eric D. DonnenfeldMD is an internationally recognized expert and pioneer in refractive, corneal and cataract surgery and one of the leading refractive and cataract surgeons in United States. Dr. Donnenfeld graduated magna cum laude from Dartmouth College in 1977 and top of his class at Dartmouth Medical School in 1980. He was chief resident at Manhattan Eye, Ear and Throat Hospital and completed a cornea and refraction fellowship at Wills Eye Hospital. Dr. Donnenfeld is a member of the Board of Supervisors at Dartmouth Medical School and Clinical Professor of Ophthalmology at New York University Medical Center.

Dr. Donnenfeld served as 2013-2014 President of the American Society of Cataract and Refractive Surgery. Dr. Donnenfeld is the medical editor of EyeWorld, the official publication of the American Society of Cataract and Refractive Surgery. He serves on the Boards of ASCRS and ACOS and is a member of the ASCRS Refractive Committee and the Cornea Section of Ocular Surgery News. Dr. Donnenfeld is National Medical Director of TLC Laser Eye Centers and Surgical Director of Lions Eye Bank of Long Island. He is a past chair of the Ocular Microbiology and Immunology Group. Locally, Dr. Donnenfeld has also served as a board member of the Nassau Academy of Medicine, the American College of Surgeons Long Island Chapter, and the Nassau Surgical Society and is a past president of the Nassau Surgical Society, where he is the youngest to ever receive their Lifetime Achievement Award.

Michael B. RaizmanMD is a Cornea and Cataract Specialist with Ophthalmic Consultants of Boston and the New England Eye Center at Tufts Medical Center. He is Medical Director of Palatin Technologies.

Dr. Raizman received his medical training at University of Michigan and Harvard Medical School. He completed two fellowships at the Massachusetts Eye & Ear Infirmary, followed by three years of postdoctoral research at Harvard Medical School, funded by grants from the National Institutes of Health. Dr. Raizman served as a full-time faculty member at Harvard Medical School from 1988-1991. Dr. Raizman is an associate professor of ophthalmology at Tufts University School of Medicine, where he has led the Cornea Fellowship Program and the Cornea and Cataract Department since 1992. In this capacity, he has trained over 50 Cornea Fellows. He is part of the medical staff of the Massachusetts General Hospital, Massachusetts Eye and Ear, and Tufts Medical Center.

About Dry Eye Disease (DED)

Dry eye is a common inflammatory condition that, if left untreated, can become extremely painful and lead to permanent corneal and vision damage. Dry eye affects the cornea and conjunctiva of the eye, causing irritation, redness, pain and blurred vision. It is estimated to affect more than 20 million people in United States. The disease is characterized by insufficient moisture and lubrication of the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, reduced quality of life and, in severe cases, permanent visual impairment. Existing dry eye therapy is generally considered inadequate by many physicians and patients, and often requires weeks or months to demonstrate activity.

About melanocortin receptor agonists and inflammation

The melanocortin (“MCr”) receptor system has effects on inflammation, immune system responses, metabolism, food intake and sexual function. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through the use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.

Many tissues and immune cells located in the eye (and other places, for example, the intestine and the kidneys) express melanocortin receptors, which allows us to directly activate the natural pathways to resolve the inflammation of the disease.

About the Palatine

Palatin is a biopharmaceutical company developing first-in-class drugs based on molecules that modulate the activity of melanocortin and natriuretic peptide receptor systems, with targeted and receptor-specific product candidates for the treatment of diseases of medical need. unsatisfied and significant commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their market potential. For more information about Palatin, please visit the Palatin website at

Forward-looking statements

Statements in this press release that are not historical facts, including statements about Palatin Technologies, Inc.’s future expectations, such as statements about the market potential of Vyleesi and other Palatin products in development , clinical trial results, potential actions by regulatory agencies, including the FDA, regulatory plans, development programs, proposed indications for product candidates, market potential for product candidates, and potential adverse impacts due to to the global COVID-19 pandemic, such as delays in regulatory review, manufacturing and supply chain disruptions, adverse effects on health care systems and disruption to the global economy, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as such erme is defined in the Private Securities Litigation Reform Act of 1995 Palatin intends that such forward-looking statements be subject to the safe harbors created herein. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results to differ materially from its historical results or from any results expressed or implied by these forward-looking statements. Palatin’s actual results may differ materially from those referred to in the forward-looking statements for reasons including, but not limited to, Palatin’s ability to establish and maintain Vyleesi’s manufacturing, marketing and distribution capability, Vyleesi’s sales in United States and elsewhere in the world, clinical trial results, regulatory actions by the FDA and other regulatory authorities and the need for regulatory approvals, Palatin’s ability to fund the development of its technology and to establish and complete clinical trials, the time and cost required to conduct clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, market acceptance of Palatin’s products and other factors discussed in Palatin’s periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.

Show original content to download multimedia:

SOURCEPalatin Technologies, Inc.


About Author

Comments are closed.